BAXTER INTL INC shareholders Q3 2020

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2020
NameSharesValueWeighting ↓
OPSEU Pension Plan Trust Fund 25,538$2,045,0000.64%
Ascension Asset Management LLC 9,850$792,0000.63%
Gifford Fong Associates 29,000$2,332,0000.62%
J. W. Coons Advisors, LLC 18,651$1,497,0000.62%
Lombard Odier Asset Management (Europe) Ltd 130,675$10,509,0000.62%
Sciencast Management LP 20,068$1,596,0000.61%
FIRST NATIONAL BANK & TRUST CO OF NEWTOWN 31,285$2,516,0000.61%
INDEPENDENT INVESTORS INC 25,940$2,086,0000.61%
MAIRS & POWER INC 602,470$48,451,0000.60%
HALL CAPITAL MANAGEMENT CO INC 9,503$763,0000.60%
AlphaCrest Capital Management LLC 68,892$5,540,0000.60%
ACCESS FINANCIAL SERVICES, INC. 13,869$1,115,0000.60%
Farmers & Merchants Trust Co of Chambersburg PA 8,685$698,0000.60%
Mechanics Bank Trust Department 37,710$3,033,0000.60%
PUTNAM INVESTMENTS LLC 3,803,933$305,912,0000.60%
abrdn plc 2,785,852$224,038,0000.60%
Marshall Wace North America L.P. 1,154,558$92,847,0000.60%
Calamos Wealth Management LLC 63,568$5,112,0000.58%
Costello Asset Management, INC 8,220$661,0000.58%
Locust Wood Capital Advisers 112,000$9,007,0000.58%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2020. To view BAXTER INTL INC's shareholder history, click here.